YouTube Chemotherapeutic agents video
Chemotherapy Types
alkylating agents, antimetabolites, microtubule targeting agents, topoisomerase, anthracyclines, monoclonal antibodies, others
Targeted therapy
Hormonal therapy (oncology)
Cancer immunotherapy
Caris
Chemotherapy Types
alkylating agents, antimetabolites, microtubule targeting agents, topoisomerase, anthracyclines, monoclonal antibodies, others
Targeted therapy
Hormonal therapy (oncology)
Cancer immunotherapy
Caris
Potential benefit
paclitaxel, docetaxel, nab-paclitaxel
gemcitabine
liposomal-doxrubicin
leuprolide, megestrol acetate
doxorubicin, epirubicin
Potential lack of benefit
irinotecan, topotecan
tamoxifen, fulvestrant, letrozole (aromatase inhibitor), anastrozole (anti-aromatase)
fluorouracil, capecitabine, pemetrexed
trastuzumab, pertuzumab
temozolomide, dacarbazine
NCCN
docetaxel 22%
etoposide 27%
gemcitabine 19%
liposomal doxorubicin 26%
paclitaxel weekly 21%
altretamine 14%
cyclophosphamide
doxorubicin
ifosfamide 12%
melphalan
oxaliplatin
paclitaxel
nab-paclitaxel 64%
vinorelbine 20%
bevacizumab 21%
aromatase inhibitors (letrozole, anastrozole)
leuprolide acetate
megestrol acetate
Platinum-resistant
nab-paclitaxel, docetaxel (anti-microtubule)
gemcitabine (antimetabolites)
doxil (anthracyclines)
leuprolide acetate (Lupron)
megestrol acetate (Megace - Antiandrogen Antiprogestogen)
etoposide 27% (topoisomerase)?
vinorelbine 20% (anti-microtubule)?
altretamine 14% (nonclassical alkylating agent)?
ifosfamide 12%, cyclophosphamide, melphalan (alkylating agents)?
Cancer immunotherapy, the new cure, too many
Ipilimumab Yervoy, Bristol-Myers Squibb
Pembrolizumab PD-1 Keytruda, Merck Aceess Program, for Keytruda
Nivolumab PD-1 Opdivo, Expanded Access Program (Compassionate Use), Bristol-Myers Squibb Access Support
Atezolizumab PD-L1 Tecentriq Atezo, Genetech/Roche, news
Liquid biopsy, ctDNA, Foundation Medicine, Qiagen
UCSF Early Phase Clinical Trials Unit, Early Phase Clinical Trials Unit, Early Phase Clinical Trials, Developmental Therapeutics
